New hires at Amgen, Eli Lilly and Zosano

Amgen

Peter Griffith has been appointed as executive vice president, finance and will also become chief financial officer of Amgen, succeeding current CFO David Meline on 1 Jan 2020.

He joins Amgen from Sherwood Canyon Group, a private equity and advisory firm, where he served as president. Previously, he retired from EY following a distinguished career, including almost 22 years as a partner. Most recently, he served as EY's global vice chair, corporate development, with responsibility for driving the firm's international growth and expanding its capabilities globally.

Griffith previously seved as EY's global managing partner, finance and corporate development and as global managing partner, operations and finance.

During his time at EY, Griffith served on the EY Global Executive Board, the EY Americas Executive Board and the Executive Board of Ernst & Young LLP.

Eli Lilly

Mike Mason is set to take on the role of senior vice president of Lilly and president of Lilly Diabetes and Lilly USA. He will succeed Enrique Conterno, who will retire from the role at the end of the year. Conterno has spent 27 years at Lilly, and spent decades working across sales, marketing, finance, business development and general management for the company.

During his time at Lilly, Mason has led its connected care business and steered its efforts to improve insulin affordability.This includes the creation of the Lilly Diabetes Solution Center, to support people in need of less expensive alternatives to their insulin. Under his leadership, this work is set to continue.

He will assume his new role on 1 January 2020.

Zosano

Zosano, a clinical-stage biopharmaceutical company, has appointed Steven Lo (pictured left) as its new president and chief executive officer.

Prior to joining Zosano, Lo served as the chief commercial officer for Puma Biotechnoly, and previously worked as senior vice president and chief commercial officer at Corcept Therapeutics.

Earlier in his career, Lo spent 13 years at Roche Group’s Genentech in roles of increasing responsibility in sales and marketing, ultimately serving as franchise head for endocrinology.

He started his career in the pharma industry at AstraZeneca, and also holds a masters degree in health administration from the University of Southern California.